About

Global New Drug Development Company

Enzychem Lifesciences Corporation is a global pharmaceutical company focused on the development of new and innovative therapies for patients with unmet medical need. With a leading R&D center in Seoul and two GMP manufacturing facilities in Seoul Korea, the company has been developing and producing APIs, contrast imaging agents and innovative new drugs. Based on Enzychem Lifesciences’ EC-18 technology platform, the company is currently developing potential therapies to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, atopic dermatitis, sepsis, acute radiation syndrome and other autoimmune disorders. EC-18, or PLAG, is a naturally synthesized substance, derived from an active ingredient in Sika deer antlers.